Cecile Zaupa

TL;DR: These results for the first time show the efficacy of oHSV against human GBM-SCs, and correlate this cytotoxic property with specific oHSVs mutations, important for designing new o HSV vectors and clinical trials.

TL;DR: The combination of G47Δ and TMZ acts synergistically in killing GSCs through oHSV-mediated manipulation of DNA damage responses and is highly efficacious in representative preclinical models and warrants clinical translation.

TL;DR: The ICP34.5 protein of herpes simplex virus (HSV) is involved in many aspects of viral pathogenesis; promoting neurovirulence, inhibiting interferon-induced shutoff of protein synthesis, interacting with PCNA and TBK1, and binding to Beclin 1 to interfere with autophagy.

TL;DR: Treatment with G47Δ-Flt3L improves survival of glioma-bearing mice and examines its antiglioma efficacy in an immunocompetent murine model to exploit possible synergies between oncolytic herpes simplex virus type 1 (oHSV-1) infection of intracranial gliomas and delivery of immune-stimulating fms-like tyrosine kinase 3 ligand (Flt2L).

TL;DR: The results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity.